CXCL2 Protéine

N° du produit ABIN7455624

Protéine Recombinant CXCL2 exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour CXCL2 Protéine (ABIN7455624)

Antigène: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Type de proteíne: Recombinant

Origine: Humain

Source: Escherichia coli (E. coli)

Pureté: Greater than 95 % as determined by reducing SDS-PAGE.

Détail du produit

Fonction: Recombinant Human C-X-C Motif Chemokine 2 is produced by our E.coli expression system and the target gene encoding Thr39-Asn107 is expressed.

Attributs du produit: Extracellular Domain Protein

Purification: Affinity purification

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM Tris-HCl, 150 mM NaCl, pH 8.0.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détail du antigène

Antigène: CXCL2 (Chemokine (C-X-C Motif) Ligand 2 (CXCL2))

Autre désignation: CXCL2

Sujet: Chemokine Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. It is secreted by monocytes and macrophages and chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. It has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. It is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. It can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.

Poids moléculaire: 7.67 KDa

UniProt: P19875

Pathways: Cellular Response to Molecule of Bacterial Origin